StreetInsider.com News Articles

CervoMed raises $10 million in registered direct stock offering

Thu, 18 Jun 2026 12:35:24 -0400

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company, announced a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, with gross proceeds expected to total $10 million before placement agent fees and other expenses.

The offering is priced at-the-market under Nasdaq rules. Closing is expected on or about June 22, 2026, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent.

The company said it intends to use net proceeds for working capital and general corporate purposes. The shares are being offered under a shelf registration statement on Form S-3 declared effective

CervoMed raises $10 million in registered direct stock offering

Thu, 18 Jun 2026 12:35:24 -0400

The company said it intends to use net proceeds for working capital and general corporate purposes. The shares are being offered under a shelf registration statement on Form S-3 declared effective

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Thu, 18 Jun 2026 12:35:00 -0400

BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Thu, 18 Jun 2026 12:35:00 -0400

H.C. Wainwright & Co. is acting as

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Thu, 18 Jun 2026 12:35:00 -0400

H.C. Wainwright & Co. is acting as

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Thu, 18 Jun 2026 12:35:00 -0400

H.C. Wainwright & Co. is acting as

Form 8-K CervoMed Inc. For: Jun 16

Thu, 18 Jun 2026 07:22:00 -0400

si-local-file:///var/storage/secattach/20260618/26662770.html

Form 8-K CervoMed Inc. For: Jun 16

Thu, 18 Jun 2026 07:22:00 -0400

si-local-file:///var/storage/secattach/20260618/26662770.html

CervoMed receives U.S. patent for neflamapimod in pure DLB to 2042

Thu, 18 Jun 2026 07:00:32 -0400

CervoMed Inc. (NASDAQ: CRVO) announced it has received a notice of allowance from the United States Patent and Trademark Office for a new patent covering the use of its drug candidate neflamapimod in the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer's disease-like tau pathology, a condition referred to as "pure DLB."

The patent covers treatment of DLB without substantial tau pathology, which can be identified through plasma levels of pTau or brain imaging. The company said the patent is expected to provide intellectual property protection into 2042, with the possibility of a longer term through

CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042

Thu, 18 Jun 2026 07:00:00 -0400

BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecting the Company’s use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer’s disease-like tau pathology, also known as “pure DLB”.

The patent will cover the treatment of DLB without substantial tau pathology, which can be characterized

CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042

Thu, 18 Jun 2026 07:00:00 -0400

BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecting the Company’s use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer’s disease-like tau pathology, also known as “pure DLB”.

The patent will cover the treatment of DLB without substantial tau pathology, which can be characterized

Wall Street Chases the Next Big Breakout

Tue, 16 Jun 2026 15:22:12 -0400